IRIS Accounts Production v25.2.0.378 03970738 Board of Directors 1.1.24 31.12.24 31.12.24 29/9/25 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh039707382023-12-31039707382024-12-31039707382024-01-012024-12-31039707382022-12-31039707382023-01-012023-12-31039707382023-12-3103970738ns15:EnglandWales2024-01-012024-12-3103970738ns14:PoundSterling2024-01-012024-12-3103970738ns10:Director12024-01-012024-12-3103970738ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3103970738ns10:SmallEntities2024-01-012024-12-3103970738ns10:Audited2024-01-012024-12-3103970738ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3103970738ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3103970738ns10:FullAccounts2024-01-012024-12-3103970738ns10:Director32024-01-012024-12-3103970738ns10:Director42024-01-012024-12-3103970738ns10:RegisteredOffice2024-01-012024-12-3103970738ns5:CurrentFinancialInstruments2024-12-3103970738ns5:CurrentFinancialInstruments2023-12-3103970738ns5:ShareCapital2024-12-3103970738ns5:ShareCapital2023-12-3103970738ns5:RetainedEarningsAccumulatedLosses2024-12-3103970738ns5:RetainedEarningsAccumulatedLosses2023-12-3103970738ns5:LandBuildingsns5:ShortLeaseholdAssets2024-01-012024-12-3103970738ns5:PlantMachinery2024-01-012024-12-3103970738ns5:FurnitureFittings2024-01-012024-12-3103970738ns5:ComputerEquipment2024-01-012024-12-3103970738ns5:LandBuildings2023-12-3103970738ns5:PlantMachinery2023-12-3103970738ns5:LandBuildings2024-01-012024-12-3103970738ns5:LandBuildings2024-12-3103970738ns5:PlantMachinery2024-12-3103970738ns5:LandBuildings2023-12-3103970738ns5:PlantMachinery2023-12-3103970738ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3103970738ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3103970738ns5:WithinOneYear2024-12-3103970738ns5:WithinOneYear2023-12-3103970738ns5:BetweenOneFiveYears2024-12-3103970738ns5:BetweenOneFiveYears2023-12-3103970738ns5:AllPeriods2024-12-3103970738ns5:AllPeriods2023-12-3103970738ns5:DeferredTaxation2023-12-3103970738ns5:DeferredTaxation2024-01-012024-12-3103970738ns5:DeferredTaxation2024-12-31
REGISTERED NUMBER: 03970738 (England and Wales)









AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

EUROIMMUN UK LIMITED

EUROIMMUN UK LIMITED (REGISTERED NUMBER: 03970738)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


EUROIMMUN UK LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2024







DIRECTORS: L Perazzotti
D Beecker
N Mitton





REGISTERED OFFICE: Ashville House
131-139 The Broadway
Wimbledon
London
SW19 1QJ





REGISTERED NUMBER: 03970738 (England and Wales)





AUDITORS: Hartley Fowler LLP
Statutory Auditors
Chartered Accountants
4th Floor Tuition House
27-37 St George's Road
Wimbledon
London
SW19 4EU

EUROIMMUN UK LIMITED (REGISTERED NUMBER: 03970738)

BALANCE SHEET
31 DECEMBER 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 625,683 715,052

CURRENT ASSETS
Stocks 348,199 320,002
Debtors 5 2,788,042 2,271,222
Cash at bank and in hand 710,367 517,543
3,846,608 3,108,767
CREDITORS
Amounts falling due within one year 6 792,674 575,952
NET CURRENT ASSETS 3,053,934 2,532,815
TOTAL ASSETS LESS CURRENT
LIABILITIES

3,679,617

3,247,867

PROVISIONS FOR LIABILITIES 8 139,208 157,122
NET ASSETS 3,540,409 3,090,745

CAPITAL AND RESERVES
Called up share capital 339,000 339,000
Retained earnings 3,201,409 2,751,745
3,540,409 3,090,745

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 September 2025 and were signed on its behalf by:





L Perazzotti - Director


EUROIMMUN UK LIMITED (REGISTERED NUMBER: 03970738)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024


1. STATUTORY INFORMATION

Euroimmun Uk Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue is measured at fair value of the consideration received or receivable. Revenue is reduced for estimated customer returns, rebates and other similar allowances.

Revenue from the sale of goods is recognised when goods are delivered and legal title has passed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Short leasehold - over the lease term
Plant and machinery - 25% on reducing balance
Fixtures and fittings - 15% on reducing balance
Computer equipment - 33% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


EUROIMMUN UK LIMITED (REGISTERED NUMBER: 03970738)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Debtors and creditors receivable / payable within one year
Debtors and creditors with no stated interest rate and receivables or payables within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

Impairment
Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 21 (2023 - 20 ) .

4. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 January 2024 79,494 1,625,489 1,704,983
Additions - 155,672 155,672
Disposals - (118,169 ) (118,169 )
At 31 December 2024 79,494 1,662,992 1,742,486
DEPRECIATION
At 1 January 2024 61,956 927,975 989,931
Charge for year 4,188 227,944 232,132
Eliminated on disposal - (105,260 ) (105,260 )
At 31 December 2024 66,144 1,050,659 1,116,803
NET BOOK VALUE
At 31 December 2024 13,350 612,333 625,683
At 31 December 2023 17,538 697,514 715,052

EUROIMMUN UK LIMITED (REGISTERED NUMBER: 03970738)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024


5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 972,923 934,396
Amounts owed by group undertakings 1,667,532 1,217,089
Other debtors 147,587 119,737
2,788,042 2,271,222

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 3,286 2,993
Amounts owed to group undertakings 338,903 169,787
Taxation and social security 384,253 334,004
Other creditors 66,232 69,168
792,674 575,952

7. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 470,968 421,935
Between one and five years 539,260 836,759
1,010,228 1,258,694

8. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 139,208 157,122

Deferred
tax
£   
Balance at 1 January 2024 157,122
Provided during year (17,914 )
Balance at 31 December 2024 139,208

The year end deferred tax liability of £139,208 (2023: £157,122) is made up of a deferred tax asset of £8,575 (2023: £8,575) and a deferred tax liability of £147,783 (2023: £165,697)

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Jonathan Askew (Senior Statutory Auditor)
for and on behalf of Hartley Fowler LLP

EUROIMMUN UK LIMITED (REGISTERED NUMBER: 03970738)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024


10. PARENT COMPANY

The smallest group in which the results of the company are consolidated is that headed by Euroimmun
Medizinische Labordiagnostika AG, with registered address Seekamp 31, 23560 Lübeck, Germany.

The largest group in which the results of the company are consolidated is that headed by Revvity Inc (formerly named PerkinElmer Inc., prior to May 2023) who are the ultimate controlling party. The consolidated accounts of this company are available to the public and may be obtained from Revvity, Inc., at 940 Winter Street, Waltham, Massachusetts 02451.